Last reviewed · How we verify
Methotrexate - DAVA
At a glance
| Generic name | Methotrexate - DAVA |
|---|---|
| Also known as | Methotrexate Sodium |
| Sponsor | Amneal Pharmaceuticals, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment (PHASE3)
- Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (PHASE2, PHASE3)
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 (PHASE3)
- Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (PHASE3)
- International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methotrexate - DAVA CI brief — competitive landscape report
- Methotrexate - DAVA updates RSS · CI watch RSS
- Amneal Pharmaceuticals, LLC portfolio CI